The extracellular domain of the human erythropoietin receptor: expression as a fusion protein in Escherichia coli, purification, and biological properties

We developed an efficient production system of the soluble extracellular domain of the human erythropoietin receptor (sEPO-R) and characterized the binding of erythropoietin (EPO) with the purified recombinant protein. The sEPO-R, fused to the maltose binding protein (MBP), was expressed as a soluble protein in the periplasm of Escherichia coli (E. coli) and did not accumulate in inclusion bodies. After lysis of the bacteria by an osmotic shock, the fusion protein was purified by affinity chromatography on amylose followed by size exclusion chromatography (SEC). Specific binding of 125I-labelled EPO to the sEPO-R was demonstrated by competitive and saturation binding assays. A single affinity class (Kd = 0.25 nM) of the binding site was evident by Scatchard analysis. This value is similar to the Kd observed between EPO and the EPO-R of high affinity present on human erythroid progenitors. The complex has a molecular size corresponding to a 1:1 complex of EPO and the fusion protein.

Chromatographic separation of recombinant human erythropoietin isoforms

Erythropoietin (EPO) is the main regulator of erythropoiesis. The human glycoprotein hormone is heterogeneous when analyzed by isoelectric focusing (IEF). We investigated the possibility of fractionating EPO isoforms using different chromatographic methods. A recombinant human EPO (rhEPO) was obtained from the culture supernatants of a human B-lymphoblastoid cell line transfected by the human EPO gene. Highly purified rhEPO preparations were obtained by immunoaffinity purification. More than fourteen isoforms were observed after IEF. Among the different methods developed for isoform fractionation, the most reproducible results were obtained by DEAE-Sephacel chromatography. Seven fractions of decreasing isoelectric point (pI) were obtained. The specific activity of these fractions measured by an immunoradiometric assay was not equally distributed.

Purification and biological activity of a recombinant human erythropoietin produced by lymphoblastoid cells

A recombinant human erythropoietin (rH-EPO) was obtained from the culture supernatants of human B-lymphoblastoid cells transfected by the human EPO gene. rH-EPO was purified by a two-step method based on immunoaffinity and ion exchange chromatography. The first step was achieved by an anti-EPO monoclonal antibody (Mab). This Mab, immobilized on Sepharose 4B, allowed a 410-fold purification of the protein. The second step consisted of ion exchange chromatography on DEAE Sephacel. The combination of these two steps results in a highly purified rH-EPO with a global yield of about 50%; the specific activity of the protein was 176,000 IU/A280. The NMR spectrum was characteristic for a well structured, single-conformation protein. The purified protein was analyzed by SDS-PAGE and isoelectric focusing. The biological activity of purified rH-EPO was measured in vivo, by the incorporation of 59Fe into red blood cells (RBC) of polycythemic mice and in vitro by the proliferative response of an EPO-dependent cell line. The purified protein expressed in lymphoblastoid cells of human origin had the same biological activity as that of urinary EPO and rH-EPO produced in other mammalian cells.

Preparation and biological properties of monoclonal antibodies against human erythropoietin

Several monoclonal antibodies (Mabs) against human erythropoietin (H-EPO) were obtained by fusion of myeloma cells with splenocytes from mice immunized with purified recombinant H-EPO. Three Mabs (D7, E14 and E73) were selected by radioimmunoprecipitation on the basis of their high affinity against H-EPO. Their dissociation constants were 0.3 nM for E14 and D7, and 17 nM for E73. The immunochemical properties of these Mabs were analyzed in respect to their capacity to react, to purify, and to inhibit the biological activities of H-EPO. a) detection by Western blotting techniques: among the 3 Mabs only D7 was effective by this technique. b) purification: the best results were observed with E14, an approximately 200-fold purification of H-EPO from culture supernatants was obtained in a single immunopurification step. c) inhibition of the biological activity: the specific binding of 125I-labelled H-EPO to its cellular receptor was inhibited by E14 and E73 but not by D7. These three Mabs exhibited similar effects as far as the inhibition of the proliferation of H-EPO dependent cells (measured by 3H-thymidine incorporation) was concerned.

Purification and partial characterization of a hepatocyte antiproliferative glycopeptide

A low molecular weight compound, which inhibits the G1-S transition in rat hepatocytes, was obtained by tryptic hydrolysis of human alpha 2-macroglobulin followed by ultrafiltration at pH 10. It was purified by high-performance liquid chromatography on mu Bondapak C18 and mu Bondapak NH2 with a practically quantitative yield; from 5.1 g of alpha 2-macroglobulin, 2.8 micrograms of purified compound were recovered. Inactivation by specific enzymes and chemical analyses showed that the inhibitor is a sialylated glycopeptide whose peptide moiety contains a pyroglutamyl residue. Its molecular mass, estimated by gel permeation chromatography, would be in the interval 3,500-4,600. However, amino acid analyses indicated that it is not yet pure. All these data suggest that alpha 2-macroglobulin could be the carrier of the precursor form of the glycopeptide.

Rat serum factors inhibiting the G1-S transition in hepatocytes. II. Properties of the low molecular weight factor

The properties were investigated of low molecular weight factors acting on the G1-S transition of baby rat hepatocytes. These factors were produced by incubating adult rat serum with trypsin or a 100,000 g liver microsomal fraction, and isolated by ultrafiltration. Enzyme degradation assays indicated that the active compound was in both cases a glycopeptide sensitive to pronase and papain and to the combination of neuraminidase and beta galactosidase. No loss of hepatocyte G1-S inhibitory activity was observed after heat treatment at pH 7.0. G50 gel filtration showed that both the G1-S inhibitory factors were collected in the last fractions eluted. The elution volume was slightly larger for the trypsin than for the microsomal-induced factor, suggesting a small difference between their molecular weight. These factors are believed to be glycopeptides with a molecular weight around 1400. They might be composed of a 3-sugar polysaccharide chain with a galactose preterminal and a neuraminic acid terminal, linked to a polypeptide chain of 6 to 8 amino acids.

Effects of conditioned medium from bone marrow of normal and Ara-C-treated mice on hemoglobin synthesis

Differentiation of CFUs toward erythropoiesis has been demonstrated in mice treated with a single dose of Ara-C, and this preferential differentiation was shown to be under the influence of diffusible factors. The aim of the work reported here was to determine whether these factors might include erythropoietin (Ep). This possibility was explored by testing the effect of the Ara-C-induced factor(s) on hemoglobin synthesis, and the effects of anti-mouse Ep on the activity of Ara-C-induced factors. When the late erythropoiesis stage of fetal liver cells was stimulated by bone-marrow-conditioned medium, no significant difference was observed between the effects of conditioned media obtained from normal versus Ara-C-treated bone marrow cells. Bone-marrow-conditioned medium induced a dose-dependent effect on hemoglobin synthesis by fetal liver cells (or adult bone marrow cells); the resulting curve was not parallel to the log-dose-response curve of purified mouse Ep. Anti-mouse Ep inhibited the activity of mouse Ep in fetal erythroblast cultures, but did not affect the stimulatory activity of conditioned media. Below the plateau doses no cumulative erythropoietic effect was observed in fetal erythroblast cultures when conditioned medium was added to Ep. Thus the present data suggest that the effect of bone-marrow-conditioned medium results from at least two independent factors: the first one active on CFUs differentiation towards erythropoiesis, and the second one active at a later stage of erythroid maturation. These factors can be considered to be molecules with an immunogenic structure unrelated to that of Ep.

A phospholipase A2 with anticoagulant activity. I. Isolation from Vipera berus venom and properties

An anticoagulant protein has been isolated by DEAE cellulose chromatography and gel filtration from the venom of the Vipera berus orientale (Eastern Europe). Purification has been completed by elution on carboxymethyl cellulose with continuous gradient at constant pH. The inhibitor of coagulation was separated from the other venom enzymes, e.g. procoagulant, fibrinogenolytic, aminoesterase and amino acid oxidase activities. It was also separated from other phospholipase components which were not related to the anticoagulant property. The inhibitor appeared as a simgle polypeptidic chain protein, formed by 119 amino acid residues, with a molecular weight of 13400 and an isoelectric point of 9.2. At low saline molarity, a monomer-trimer transition of this protein was observed. Both forms had the same amino acid composition. There were six disulfide bridges without free SH groups per phospholipase molecule. Deprived of any proteolytic activity, the clotting inhibitor displayed a high phospholipase activity in the presence of calcium. Activity did no appear with EDTA buffer deprived of cation. Finely dispersed micellar suspensions were found suitable for obtaining the highest phospholipase activity. High sodium cholate concentration or methanol/chloroform/ether solvent were effective without loss of enzymatic activity. As characteristis of phospholipase A2 (EC 3.1.1.4), the degradation products identified on thin-layer chromatography induced hemolysis of human erythrocytes. The apparent Km value 1.25 - 10(-3) M was determined on phosphatidylcholine isolated from ovolecithin. This purified berus inhibitor would be of value for investigating the involvement of phospholipids in the clotting mechanism.